ArticleFamilial cancer2026
Histopathological and immunohistochemical analyses do not indicate timing of prophylactic hysterectomy: a retrospective analysis of endometrial biopsies in Lynch syndrome carriers.
Article in Familial cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Women with Lynch syndrome are at increased risk of endometrial cancer. Gynecological surveillance is advised, but also prophylactic hysterectomy is an option. This study aimed to gain more insight in tumorigenesis in Lynch carriers to be able to personalize prophylactic hysterectomy timing. To this aim endometrial cancer surveillance in Lynch syndrome carriers was assessed using data from the Dutch Lynch syndrome database linked to the Dutch National Pathology Databank (PALGA). Eligible participants were Lynch syndrome carriers under surveillance, who underwent hysterectomy and had ≥ 1 endometrial biopsy within five years prior to surgery. Pathology reports, describing the histopathological features of the samples, were collected and, if available, samples were revised by a specialized pathologist. Additionally loss of expression of ARID1A, PTEN, PAX2, and mismatch repair (MMR) proteins was studied. Pathology reports from 32 Lynch syndrome carriers were analyzed: 16 had normal endometrium at hysterectomy, five had hyperplasia without atypia, six had endometrial intra-epithelial neoplasia (EIN), and five had endometrial cancer. Prior to hysterectomy, hyperplasia with or without atypia or endometrial cancer was reported in 3% of biopsies in the histopathological normal group, 26% in endometrial hyperplasia without atypia group, 26% in the EIN group, and 36% in the endometrial cancer group. Upon revision, combined neoplastic development of tissue and loss of protein expression were observed in 12% of the normal group, 36% of endometrial hyperplasia without atypia, 36% of EIN, and 50% of endometrial cancer group. So, increasing tissue disorganization and loss of protein expression appeared to correlate with progression to (pre)malignancy. However, no specific marker or consistent pattern emerged that could guide clinical decisions on prophylactic hysterectomy for individual patients. These findings highlight the complexity of endometrial cancer development in Lynch syndrome and underscore the need for further research to improve surveillance strategies and optimize timing of prophylactic surgery.
Indexed as
Identifiers
42878963What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.